Day of Record: Apple Inc. (NASDAQ: AAPL), Google Inc. (NASDAQ: GOOG) and, Inc. (NASDAQ: BIDU) shares grow

Apple Inc. (NASDAQ: AAPL) shares seek higher

In brief: Apple Inc. (NASDAQ: AAPL), Google Inc. (NASDAQ: GOOG) and, Inc. (NASDAQ: BIDU) are taking trading in the green zone. Trading volumes are growing every minute.

Apple Inc. (NASDAQ: AAPL) may rise, – the experts say. Today’s trading day is favorable for high technologies and the Internet. High-tech companies’ shares are growing rapidly. Bullish trend has engulfed the market from the outset.

Apple Inc. (NASDAQ: AAPL) proved capable to hush the Asian scandal rising up to 251.76 points, gaining +4.12 (1.66%). The main competitor Apple – Google Inc. (NASDAQ: GOOG) rises at slower pace. Google Inc. shares rose by +2.52 (0.52%) to 488.11. The Chinese search engine, Inc. (Public, NASDAQ: BIDU) went up to 85.70 points, regaining +1.35 (1.60%) with the bears. Analysts predict the growth of Internet companies by 1,5-2% today.

Igor Tringlers
2010-08-17 14:42, Economics.

News on: , , , , , , , ,

One comment к “Day of Record: Apple Inc. (NASDAQ: AAPL), Google Inc. (NASDAQ: GOOG) and, Inc. (NASDAQ: BIDU) shares grow”

  1. INC. (OXGN) return Says:

    INC. (OXGN) return 17-Aug-10 04:42 am
    One observation that I certainly can sympathize with.

    Most of what has been written about Orexo the past month have failed to create any meaningful discussion of the company.

    However, I would like to take this opportunity and try to launch such a discussion. I have read previous posts by you both and understand that you have invested it all. is invested in commercial sales.

    I have not been inside the shares for long but still turned the modest valuation. …Especially in light of the agreements they rowed ashore and took account of Abstral which seems to be the market leader in several countries.

    Also understand that the “company” is better than “shares” and that it probably requires a considerable momentum to launch a sustained appreciation.

    Triggers in the near future is – as I understand it – response from Canada (Aug), response from the FDA (Aug / Sep), response from Russia (Aug / Sep?) And of course interim report.

    What’s the risk it all. opportunities do you see in the medium term?

    What can we expect from the report? The sales figures ought to be from Italy? If I understand correctly, so this is expected to become a major market for Abstral.

    Which currency effects, we can expect and how do you think this affects the outcome?

    What are the possibilities for Abstral when it comes to off-label ‘Prescription? Is not that good track of how similar REMS program looks in the EU. In the U.S. they seem to at least have introduced a relatively tough regulation that does not promote secondary uses.

Post a comment